Verrica Pharmaceuticals Inc.
No enriched coverage for $VRCA in the last 7 days.
No SEC Form 4 filings for $VRCA in the last 30 days.
See all $VRCA insider activity →Verrica Pharmaceuticals Inc. (VRCA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d13828dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results – Company reports record demand for YCANTH ® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-ov
Verrica Pharmaceuticals Inc. (VRCA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d139416dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 A MENDED AND R ESTATED 2018 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : M ARCH 22, 2026 A PPROVED BY THE S TOCKHOLDERS : J UNE 5, 2026 E FFECTIVE D ATE : J UNE 5, 2026 1. G ENERAL . (a) Successor to and
Verrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company's trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.
Recent VRCA coverage spans financial news, earnings and corporate actions.
The 8-K provides fresh operating metrics for YCANTH and updates the funding runway via a new up to $27.5M credit facility, supporting near-term risk management and longer-dated clinical optionality.
Board/officer updates plus equity-plan amendment can affect dilution expectations and near-term sentiment, but no clinical/financial guidance is provided here.
Verrica Pharmaceuticals reported a Q4 loss despite revenue growth, raising concerns about its path to profitability. The company's net loss and cash position suggest potential downside risk, but strong revenue growth indicates some positive momentum.
Verrica Pharmaceuticals reported mixed quarterly earnings: EPS missed estimates, but revenue beat expectations. The stock's sentiment is somewhat bearish, with institutional ownership at 42.45%.
Verrica Pharmaceuticals' announcement of initiating Phase 3 trials for YCANTH (VP-102) for common warts indicates progress in dermatology therapeutics. The news is likely to positively influence VRCA stock, reflecting potential for market expansion and future revenue growth.
alphai scores every news story that mentions VRCA with an AI model for sentiment and relevance, and aggregates insider trades from Verrica Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Verrica Pharmaceuticals Inc. (VRCA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d13828dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results – Company reports record demand for YCANTH ® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-ov
7 min readVerrica Pharmaceuticals Inc. (VRCA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d139416dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 A MENDED AND R ESTATED 2018 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : M ARCH 22, 2026 A PPROVED BY THE S TOCKHOLDERS : J UNE 5, 2026 E FFECTIVE D ATE : J UNE 5, 2026 1. G ENERAL . (a) Successor to and
6 min readVerrica Pharmaceuticals reported a Q4 basic EPS loss of US$0.57, despite revenue growth throughout 2025, leading to renewed debate on its path to sustainable profitability. The company's trailing twelve-month revenue was US$35.6 million with a net loss of US$17.9 million, highlighting that increased sales have not yet offset operating costs. While growth forecasts are strong, concerns remain over deepening losses, a short cash runway, and shareholder dilution.
3 min readVerrica Pharmaceuticals (NASDAQ:VRCA) announced its quarterly earnings, reporting an EPS of ($0.51), missing the consensus estimate of ($0.43). However, the company's revenue of $5.09 million surpassed analysts' expectations of $4.52 million. The stock currently holds an average "Hold" rating from analysts with an average price target of $17.00, and institutional investors own 42.45% of the company's stock.
3 min readVerrica Pharmaceuticals announced the dosing of the first patient in its global Phase 3 program for YCANTH (VP-102) to treat common warts, a condition affecting 22 million U.S. patients with no FDA-approved prescription therapies. This milestone follows promising Phase 2 COVE-1 study results showing 51% complete clearance of warts, indicating YCANTH's potential to become the first approved treatment for common warts in the U.S. and Japan. The company views this as a significant step for YCANTH's label expansion, offering substantial commercial and licensing opportunities.
2 min readProceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors. Caligan Partners entitled to designate a new member to ...
2 min read- Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue ...
2 min readWEST CHESTER, Pa., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Verrica Pharmaceuticals Inc. ( "Verrica" ) ( NASDAQ:VRCA ) , a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral ...
3 min readWEST CHESTER, Pa., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Verrica Pharmaceuticals Inc. ( "Verrica" ) ( Nasdaq: VRCA ) , a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral ...
2 min read- Approval triggers $10 million cash milestone payment to ...
2 min read
